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OBJECTIVE: To assess the cross-sectional validity of the
patients’ attitudes and perceptions towards HAART question-
naire. METHODS: Epidemiological, cross-sectional, multicentre
study, where 35 Spanish HIV specialists took part. HIV-infected
highly antirretroviral-experienced patients over 18, who had
been treated with Fusion Inhibitors, were included. A question-
naire was developed to collect information about patients’ global
health perception, HIV treatment and health care received. Ques-
tions were grouped into ﬁve dimensions: treatment satisfaction
(TS) (0–10), treatment affectation in daily situations (TADS)
(0–28), psychological affectation due to treatment (PAT) (0–36)
and side effects (PASE) (0–52) and health care importance (HCI)
(0–24), where 0 indicates, a higher TS, lower TADS, PAT and
PASE, and a higher HCI. Total score was calculated for each of
the domains. Therapeutic adherence was evaluated through the
SMAQ questionnaire. RESULTS: A total of 258 patients were
included. Mean age (SD) was 44.5 (8.1) years, 77.8% were men
and 62.7% of the patients were in stage C. In all questionnaire’s
dimensions, a Cronbach’s alpha higher than 0.70 was obtained,
except for TS (Cronbach’s alpha = 0.40). Patients who reported
better health status had lower scores (higher satisfaction) in the
different dimensions of the questionnaire. This indicates, higher
TS (p < 0.01), lower TADS (p = 0.045), lower PAT and PASE 
(p < 0.01) and a higher HCI, although in the HCI dimension no
signiﬁcant differences were found. Adherent patients had lower
scores in TS dimension (p < 0.01), PAT (p = 0.008) and PASE (p
= 0.008). Patients without side effects had lower values in PASE
(p = 0.028). CONCLUSION: The patients’ attitudes and per-
ceptions towards HAART therapy questionnaire is a suitable
tool for the clinical management of HIV-infected patients. There
is a clear relation between satisfaction and adherence, global
health status and presence of side effects in advanced HIV-
infected patients.
MENTAL HEALTH
PMH1
COST-EFFECTIVENESS OF CLINICALLY PROVEN TREATMENT
STRATEGIES FOR ATTENTION-DEFICIT/HYPERACTIVITY
DISORDER (ADHD): IMPACT OF COEXISTING CONDITIONS
Schlander M1, Schwarz O1, Foster EM2, Hakkaart-van Roijen L3,
Jensen PS4, Persson U5, Santosh PJ6,Trott GE7, MTA Cooperative
Group O8
1Institute for Innovation & Valuation in Health Care (InnoVal-HC),
Eschborn, Germany, 2University of North Carolina, Chapel Hill, NC,
USA, 3Institute for Medical Technology Assessment (iMTA),
Rotterdam,The Netherlands, 4Columbia University, New York, NY,
USA, 5The Swedish Institute for Health conomics, IHE, Lund, Sweden,
6Institute of Child Health—Great Ormond Street Hospital, London,
UK, 7University of Wuerzburg, Aschaffenburg, Germany, 8National
Institutes of Mental Health, Bethesda, MD, USA
Most patients with ADHD suffer from coexisting conditions,
notably oppositional deﬁant disorder and conduct disorder
(“externalizing”, in ∼50–60%) or anxiety and depression
(“internalizing”, in 12–26%). Yet, the impact of comorbidity on
the cost-effectiveness of clinically proven treatment strategies for
ADHD is poorly understood. OBJECTIVES: To combine data
on symptom normalization and functional improvement from
the NIMH MTA Study (enrolling n = 579 children with ADHD
according to DSM-IV-criteria) with data on resource utilization,
in order to explore the relevance of coexisting conditions for
cost-effectiveness of MTA-type treatment strategies, i.e., med-
ication management (MedMgt), intense behavioral management
(Beh), and the two combined (Comb), versus (United States)
community care (CC) and a hypothetical “Do Nothing” alter-
native (time horizon 14 months). METHODS: Patient subgroups
were deﬁned by coexisting conditions: pure ADHD (n = 184,
∼32%), ADHD and internalizing (n = 81, ∼14%) or externaliz-
ing (n = 172, ∼30%) comorbidities only, or ADHD and both
comorbidities (n = 142, ∼25%). Resource utilization data from
the MTA Study were combined with country-speciﬁc unit costs
(Germany, The Netherlands, Sweden, UK, and United States;
year 2005). SNAP-IV scores <1 deﬁned symptomatic “respon-
ders”, whereas functional improvement was measured as effect
size (ES) changes in Columbia Impairment Scale scores. Cost-
effectiveness was determined calculating incremental cost-effec-
tiveness ratios (ICERs) and cost-effectiveness acceptability curves
(CEACs). RESULTS: In terms of symptomatic improvement,
MedMgt represented the economically most attractive strategy
across jurisdictions and comorbidities (ICERs versus CC ranging
from €100 to €5000 per patient “normalized”, dominating Beh).
In terms of functional improvement, MedMgt was attractive at
low levels of willingness-to-pay, whereas Beh was more attrac-
tive at moderately higher levels of willingness-to-pay for patients
with internalizing comorbidity, and Comb became more attrac-
tive in the presence of externalizing comorbidities. CON-
CLUSIONS: The observed pattern of cost-effectiveness by
comorbidity was remarkably similar across jurisdictions. Further
research is needed to determine the relative merits of better-tar-
geted, less expensive behavioral interventions.
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OBJECTIVES: To estimate the prevalence of Metabolic Syn-
drome (MS) in patients with Bipolar Disorder (BD) in a Health
Management Organization. METHODS: Cross-sectional study
assessing the administrative claim database of Badalona Serveis
Assistencials. All patients above 15 years, both sexes, on BD
therapy for more than 2 months were included in the study
cohort. The control group was formed for the rest of patients in
the BSA database without BD. MS was deﬁned according with
NCEP ATP III-modiﬁed criteria and required fulﬁlment of 
at least 3 of following 5 components: body mass index (BMI)
>28.8 kg/m2, triglycerides >150 mg/dl, HDL-cholesterol <40 mg/dl
(men)/<50 mg/dl (women), blood pressure >130/85 mmHG, and
fasting glucose >110 mg/dl. Descriptive statistics, bivariate
analysis and logistic regression models were applied. RESULTS:
We identiﬁed 178 patients with BD out of 86,028 subjects
(50.5% women; 45.5 + 17.8 years, mean + SD) included in BSA
database. MS prevalence was signiﬁcantly higher in BD; 24.7%
(95%CI, 18.6%–31.7%) vs 14.4% (14.2%–14.7%); age
adjusted OR = 1.65 (1.11–2.44, p = 0.013). All components of
MS were higher in BD group, particularly high BMI [33.1%
(26.3%–40.6%) vs 17.9% (17.7%–18.2%), adjusted OR = 2.05
(1.46–2.87, p < 0.001)], high tryglicerides [23.0% (17.1%–
